Abstract | BACKGROUND & AIMS: METHODS: In this multicenter randomized non-inferiority trial, 174 patients with HBV resistant to multiple drugs ( lamivudine, entecavir, and/or adefovir) under TDF monotherapy for ≥96 weeks were randomized 1:1 to switch to TAF (n = 87) or continue TDF (n = 87) for 48 weeks. The primary endpoint was proportion of patients with HBV DNA <60 IU/mL at week 48. RESULTS: At baseline, 84 and 80 patients had HBV DNA <60 IU/mL in the TAF and TDF groups, respectively. At week 48, the proportion of patients with HBV DNA <60 IU/mL was 98.9% (86/87) in TAF group, showing non-inferiority to TDF group (97.7%, 85/87; difference, 1.1%; 95% confidence interval, -2.7% to 5.0%). Changes in median alanine aminotransferase at week 48 from baseline were statistically different between TAF and TDF groups (-3 IU/L vs +2 IU/L; P = .02). TAF group showed a statistically greater increase in bone mineral density at spine (+1.84% vs +0.08%; P = .01) and numerically higher increase in mean estimated glomerular filtration rate (+8.2% vs +4.5%; P = .06) compared with TDF group. Compared with TDF group, TAF group showed significantly greater increases in mean body weight (0.71 vs -0.37 kg; P = .01) and total, low-density lipoprotein, and high-density lipoprotein cholesterol levels (P < .001 for all) at week 48 from baseline. CONCLUSIONS: TAF could be substituted for TDF in patients with multidrug-resistant HBV for improved bone and renal safety without a loss of efficacy. However, increases in body weight and cholesterol levels with TAF treatment would be a concern. ClinicalTrials.gov no.: NCT03241641.
|
Authors | Kwan Soo Byun, Jonggi Choi, Ji-Hoon Kim, Yung Sang Lee, Han Chu Lee, Yoon Jun Kim, Byung Chul Yoo, So Young Kwon, Geum-Youn Gwak, Young-Suk Lim |
Journal | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
(Clin Gastroenterol Hepatol)
Vol. 20
Issue 2
Pg. 427-437.e5
(02 2022)
ISSN: 1542-7714 [Electronic] United States |
PMID | 33962041
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Antiviral Agents
- Tenofovir
- tenofovir alafenamide
- Alanine
|
Topics |
- Alanine
(therapeutic use)
- Antiviral Agents
(therapeutic use)
- Hepatitis B
(drug therapy)
- Hepatitis B, Chronic
(drug therapy)
- Humans
- Tenofovir
(analogs & derivatives, therapeutic use)
- Treatment Outcome
|